knowledge -WSS

knowledge

author：Wikipedia 2025-08-04 12:32:02 - browse：297

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： 3 medical device trends to watch in 2024

focus

hotspot

WSS

What to know about Virgin Galactic's 1st mission taking paying customers to space

Ahead of JPM, here's who's profiting most in health care

GSK Flovent asthma inhalers replaced by authorized generics

U.K. sequencing study surfaces new findings about tumor DNA

Naloxone nonprofit donates 200,000 doses after FDA approval

Anavex keeps shifting the goalposts in its clinical trials

entertainment

knowledge

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Methadone doses haven’t kept up in the age of fentanyl

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

What does generative AI mean for health care? We asked experts

U.K. sequencing study surfaces new findings about tumor DNA

At least 13 dead in Texas as scorching temps continue

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Moonlake's readout produced a cash windfall. Risks remain

3 trends to watch in health tech's hiring outlook for 2024

explore

Drastic changes should bring profitability, startup health insurers say

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

American woman, child freed after being kidnapped in Haiti last month

focus

hotspot

focus

focus